Availability of anti-tuberculosis drugs in Europe

European Respiratory Journal

Volumn 40, Issue 2, 2012, Pages 500-503

  Sotgiu, Giovanni ^a   D'Ambrosio, Lia ^b   Centis, Rosella ^b   Bothamley, Graham ^e   Cirillo, Daniela M ^c   De Lorenzo, Saverio ^d   Guenther, Gunar ^f   Kliiman, Kai ^h   Muetterlein, Ralf ^g   Spinup, Victor ⁱ   Villar, Miguel ^j   Zellweger, Jean Pierre ^k   Sandgren, Andreas ^l   Huitric, Emma ^l   Lange, Christoph ^f   Manissero, Davide ^l   Migliori, Giovanni Battista ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d Reference Hospital for MDR and HIV TB   (Italy)

^e HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^f RESEARCH CENTER BORSTEL   (Germany)

^g Parsberg Hospital   (Germany)

^h UNIVERSITY OF TARTU   (Estonia)

ⁱ MDR TB Centre   (Romania)

^j Lung Diseases Centre of Venda Nova   (Portugal)

^k Swiss Lung Association   (Switzerland)

^l EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE; TUBERCULOSTATIC AGENT;

DRUG BIOAVAILABILITY; DRUG COST; DRUG QUALITY; EUROPE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FUNDING; HEALTH CARE POLICY; HUMAN; INCIDENCE; INCOME; LETTER; MULTIDRUG RESISTANT TUBERCULOSIS; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; DRUG INDUSTRY; DRUG THERAPY; EUROPE; HUMANS; PHARMACEUTICAL PREPARATIONS; PROGRAM DEVELOPMENT; QUESTIONNAIRES; TUBERCULOSIS;

EID: 84864740146     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00009212     Document Type: Letter

References (11)

1. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871-881.
2. Ködmön C, Hollo V, Huitric E, et al. Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area. Eurosurveillance 2010; 15: 19519.
3. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626. (Pubitemid 351194820)
4. Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 2006; 367: 952-955.
5. Capstick TG, Laycock D, Lipman MC, et al. Treatment interruptions and inconsistent supply of anti-tuberculosis drugs in the United Kingdom. Int J Tuberc Lung Dis 2011; 15: 754-760.
6. Sotgiu G, Centis R, D'ambrosio L, et al. Development of a standardised tool to survey MDR-/XDR-TB case management in Europe. Eur Respir J 2010; 36: 208-211.
7. MiravitllesM, Ferrara G, Lange C, et al. TB or not TB: update fromthe ERS Respiratory Infection Assembly 10. Eur Respir J 2010; 36: 665-670.
8. Sotgiu G, D'Ambrosio L, Centis R, et al. TB and M/XDR-TB infection control in European TB reference centres: the Achille's heel? Eur Respir J 2011; 38: 1221-1223.
9. Migliori GB, Sotgiu G, D'Ambrosio L, et al. TB and MDR/XDR-TB in European Union and European Economic Area Countries: managed or mismanaged? Eur Respir J 2012; 39: 619-625.
10. Migliori GB, Sotgiu G, Blasi F, et al. European Union Standards for Tuberculosis Care. Eur Respir J 2011; 38: 493-495.
11. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.